Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne Inks Deal for Access to B-MoGen Gene-Editing Technology

NEW YORK (GenomeWeb) – Bio-Techne has signed a deal to gain access to B-MoGen Biotechnologies' gene-editing technology, the companies announced today. As part of the arrangement, Bio-Techne has also made an unspecified seed investment in B-MoGen.

Specific details about the technology were not disclosed, but B-MoGen offers genome modification services that use targeted nucleases to delete genes, exons, or genomic regions, or to insert specific sequences into the genome. The company has also filed a patent application on a single-step method for isolating gene-edited cells.

"B-MoGen is a terrific investment in an emerging field of novel molecular and discovery tools that … provides a strong technological foundation for Bio-Techne to explore new generations of high-quality protein, antibody, and cellular reagents, build innovative assays and instruments, and continue strongly as the leader in this life science field," Bio-Techne CTO Fernando Bazan said in a statement.